主要文件

查看所有文档

SML1750

Fidaxomicin

Name: Fidaxomicin
Brand: SIGMA

From Actinoplanes deccanensis, ≥95% (HPLC), bacterial transcription inhibitor, powder

别名:

Clostomicin B1, Lipiarmycin A3, OPT 80, Tiacumicin B

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₅₂H₇₄Cl₂O₁₈

化学文摘社编号:

873857-62-6

分子量:

1058.04

UNSPSC Code:

12352200

PubChem Substance ID:

329826053

NACRES:

NA.77

MDL number:

MFCD27976367

Assay:

≥95% (HPLC)

Form:

powder

Quality level:

200

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

Fidaxomicin, ≥95% (HPLC)

biological source

(Actinoplanes deccanensis)

Quality Level

200

assay

≥95% (HPLC)

form

powder

solubility

DMSO: soluble 1 mg/mL, chloroform: soluble 10 mg/mL, methanol: soluble 10 mg/mL

shipped in

ambient

storage temp.

2-8°C

SMILES string

ClC1=C(CC)C(C(O[C@H]2[C@H](O)[C@H](OC)[C@H](OC/C3=C\C=C\C[C@H](O)/C(C)=C/[C@H](CC)[C@@H](O[C@]4([H])OC(C)(C)[C@@H](OC(C(C)C)=O)[C@H](O)[C@@H]4O)/C(C)=C/C(C)=C/C[C@]([C@H](O)C)([H])OC3=O)O[C@@H]2C)=O)=C(O)C(Cl)=C1O

InChI

1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1

InChI key

ZVGNESXIJDCBKN-UUEYKCAUSA-N

说明

Biochem/physiol Actions

Therapeutic dosage of fidaxomicin is found have less bactericidal effect on the bowel microbiota and reduces the recurrence of C. difficile infection.

Fidaxomicin is a first-in-class macrocyclic antibacterial agent for gram positive bacteria treatment, notably Clostridium difficile infections.

Fidaxomicin is a first-in-class macrocyclic antibacterial agent for gram positive bacteria treatment, notably Clostridium difficile infections. Fidaxomicin produces its antibacterial effects by inhibiting bacterial RNA polymerase at transcription initiation. Furthermore, Fidaxomicin is an inhibitor of bacterial transcription. Fidaxomicin acts at an earlier step in the transcription initiation pathway. Specifically, Fidaxomicin binds to the DNA template-RNA polymerase complex and prevents the initial separation of DNA strands, which precedes messenger RNA synthesis by inhibiting the s subunit. Fidaxomicin′s unique target site may explain its limited spectrum of antimicrobial activity because s subunits differ among bacterial species.

Other Notes

Chemical name: [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9Z,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-Dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

0000530598

0000457187

0000212512

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis.

M S Osburne et al.

Journal of virology, 33(3), 945-953 (1980-03-01)

We have used lipiarmycin, a specific inhibitor of initiation of transcription, to study the role of host RNA polymerase in the transcription programs of various phages of Bacillus subtilis. Unlike rifampin, lipiarmycin preferentially inhibits transcription dependent on the sigma subunit

Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.

Alan P Johnson

Current opinion in investigational drugs (London, England : 2000), 8(2), 168-173 (2007-03-03)

Optimer Pharmaceuticals Inc, in collaboration with Par Pharmaceutical Companies Inc, is developing OPT-80, a narrow-spectrum macrocyclic antibiotic secreted by the actinomycete Dactylosporangium aurantiacum, for the potential treatment of Clostridium difficile-associated diarrhea (CDAD) and vancomycin-resistant Enterococcus infection. A phase IIb/III clinical

Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin.

Maxime Gualtieri et al.

Antimicrobial agents and chemotherapy, 50(1), 401-402 (2005-12-27)

查看所有相关文献

全球贸易项目编号

货号	GTIN
SML1750-1MG	04061823016940